The prostate cancer vaccine pipeline is littered with casualties – from the commercial failure of Dendreon Corporation’s approved Provenge (sipuleucel-T) to the late-stage clinical failure of Bavarian Nordic A/S’s Prostvac (rilimogene galvacirepvec) monotherapy and CureVac BV’s mRNA-based CV9104. And time and again, while cancer vaccines across a range of tumor types have shown promise in stimulating an immune response, they have subsequently failed to show clinical improvement in key endpoints that matter to patients, like overall survival.
Nevertheless, an immense investment in immunotherapy R&D, particularly in oncology, continues to support a populous ecosystem of cancer vaccine developers....
